Compare RVSN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | ENSC |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.6M |
| IPO Year | 2018 | 2017 |
| Metric | RVSN | ENSC |
|---|---|---|
| Price | $3.10 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.6K | ★ 523.6K |
| Earning Date | 08-26-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,066,650.00 |
| Revenue This Year | $169.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.23 |
| 52 Week High | $9.39 | $2.26 |
| Indicator | RVSN | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 57.92 |
| Support Level | $0.24 | $0.47 |
| Resistance Level | $5.09 | $0.53 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 33.32 | 56.57 |
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.